Triple Antiviral Therapy Promising for Mild-to-Moderate COVID-19
Duration of viral shedding shorter with combination of lopinavir-ritonavir, ribavarin, interferon beta-1b
Hydroxychloroquine Has No Impact on Outcomes in COVID-19
No link seen between use of the drug and risk for composite end point of intubation or death
Risk for SARS-CoV-2 Lower for Prostate Cancer Patients on ADT
Risk reduced fourfold with androgen-deprivation therapy versus other treatment for prostate cancer
Asthma, COPD Medication Adherence Up During Pandemic
Authors say increased adherence may reflect patient concern about controlling primary respiratory illness
Symptomatic COVID-19 Infection Fatality Rate 1.3 Percent in U.S.
County-specific infection fatality rates for symptomatic cases varied from 0.5 to 3.6 percent
Physician’s Briefing Weekly Coronavirus Roundup
Here is what the editors at Physician's Briefing chose as the most important COVID-19 developments for you and your practice for the week of...
ACE Inhibitor/ARB Use Not Tied to COVID-19 Test Positivity
No significant association identified in overlap propensity score weighting analysis
New York State Reports Cases of Pediatric Inflammatory Syndrome Tied to COVID-19
Pediatric patients presenting with compatible symptoms should undergo SARS-CoV-2 testing
Anticoagulation May Improve Outcomes in COVID-19 Patients
Longer duration of AC treatment linked to reduced risk for mortality in hospitalized patients
GI Symptoms Seen in Less Than 10 Percent of COVID-19 Patients
Outpatients with new-onset GI symptoms should be monitored for COVID-19 symptoms
